Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors

KRAS mutation is a significant driving factor of tumor, and KRAS(G12V) mutation has the highest incidence in solid tumors such as pancreatic cancer and colorectal cancer. Thus, KRAS(G12V) neoantigen-specific TCR-engineered T cells could be a promising cancer treatment approach for pancreatic cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Qi, Li, Fanlu, Zou, Siyi, Zhang, Zehui, Jin, Yangbing, Jiang, Lingxi, Chen, Hao, Deng, Xiaxing, Peng, Chenghong, Mou, Nan, Wen, Chenlei, Shen, Baiyong, Zhan, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243368/
https://www.ncbi.nlm.nih.gov/pubmed/37287989
http://dx.doi.org/10.3389/fimmu.2023.1161538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243368/
https://www.ncbi.nlm.nih.gov/pubmed/37287989
http://dx.doi.org/10.3389/fimmu.2023.1161538

Ejemplares similares